EQ Equillium, Inc.

NASDAQ
$1.10

Equillium, Inc. (EQ) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.06 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -19.1% since its last earnings release on November 12, 2026.

Equillium Beat Consensus Estimates
Thursday, November 12, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.06)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.17

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Equillium, Inc.

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.